Common Joint Supplement Tied to Quicker Dementia Worsening in People With Mild Cognitive Impairment

For many people with arthritis or persistent joint discomfort, glucosamine has become a familiar supplement for daily mobility and comfort. It is widely sold, often combined with chondroitin, and commonly promoted as a way to support cartilage and help joints move more easily. With nearly 59 million Americans diagnosed with arthritis and research suggesting the number of people living with joint pain may be even higher, interest in joint supplements remains strong. That is why new research examining a possible link between glucosamine and dementia progression is drawing notice from people looking for safe and effective ways to manage joint health.

The study, published in Nature Metabolism, explored whether glucosamine use might be associated with how quickly dementia develops or worsens. The key question was not whether glucosamine causes Alzheimer’s disease or related dementias, but whether it could affect the course of these conditions after they are already present. The report notes that glucosamine is one of the most commonly used supplements among older adults, making any possible connection to cognitive health especially important to understand.

The research team, which included biochemist Ramon C. Sun, Ph.D., at the University of Florida College of Medicine, analyzed health records from patients seen at University of Florida Health facilities over an extended period. They focused on two groups: people diagnosed with Alzheimer’s disease and related dementias, often grouped together as ADRD, and people with mild cognitive impairment, or MCI, which is sometimes considered an early stage of cognitive decline that has not yet advanced to dementia.

About 8% of people in each group reported taking glucosamine. That amounted to 1,896 individuals with ADRD and 2,750 with mild cognitive impairment. A closer look at the records showed that among people with mild cognitive impairment, glucosamine users were 25% more likely to progress to dementia during the study period. In the group that already had Alzheimer’s disease or related dementias, glucosamine use was linked to a 25% higher chance of death over the 10-year analysis window.

Those figures may sound worrisome, but the researchers and outside specialists stress an important point: the study found an association, not proof of cause and effect. It did not show that glucosamine directly triggered these outcomes. Other factors could have influenced the results, so the findings should be treated cautiously until more research is done.

To probe what might be happening biologically, the investigators went beyond patient records and used laboratory models. They studied genetically modified mice designed to reflect aspects of Alzheimer’s disease and examined how glucosamine affected glycosylation, a cellular process in which sugar chains called glycans are attached to proteins. Glycosylation helps determine how proteins fold, move through cells, and function. In the brain, it also affects how neurons communicate and how learning and memory work.

In the mouse models, glucosamine increased glycosylation and was associated with poorer memory performance. When the researchers reduced this activity, memory improved in the mice. They also examined human brain tissue and found that people with Alzheimer’s disease had higher glycosylation levels than those without the condition. They described this as hyperglycosylation and said it involved proteins linked to amyloid and tau, two hallmarks strongly associated with dementia.

Sun said the findings suggest glycosylation may be a common feature of Alzheimer’s disease rather than something limited to a single experimental setup. In this view, a brain already affected by dementia has a changed biological environment in which normal processes, including glycosylation, behave differently. Glucosamine appears to feed into the pathway the body uses to create these sugar chains, and it does so while bypassing a major regulatory checkpoint, effectively adding extra raw material to the system.

In a healthy brain, Sun says, that added input from glucosamine does not appear to matter. In a brain already affected by Alzheimer’s disease or related dementias, however, the pathway seems to be overactive. More glucosamine may further increase the production of sugar chains attached to important neuronal proteins. If those proteins become too heavily glycosylated, it could interfere with signaling between neurons and potentially worsen cognitive symptoms.

Even so, both Sun and independent experts emphasize that the work remains preliminary. It points to a plausible biological pathway and a statistical association in patient data, but it does not prove that glucosamine speeds dementia or shortens life in people with cognitive disorders. Sun says the next step should be a prospective clinical trial that follows people over time and controls for other variables, which could offer clearer answers about whether glucosamine has a direct effect.

Neurologist Clifford Segil, D.O., of Providence Saint John’s Health Center, offered a similar take. He called the findings interesting and thought-provoking, but not enough to change how he treats patients with arthritis who use glucosamine for joint pain. He noted that much of the evidence comes from animal studies and from genetic manipulation of metabolic pathways, which does not translate neatly to human outcomes in people with memory loss. In his view, the research raises questions rather than settling them.

It is also important to consider who was included in the study. Sun pointed out that the concern was seen in people whose brains were already affected by cognitive impairment or dementia. The analysis did not include healthy individuals without those conditions, and the researchers are not saying glucosamine is a problem for them based on current evidence. That distinction matters for older adults who use glucosamine for joint health but have no known cognitive issues.

At a broader level, the study is a reminder that dietary supplements should not be viewed as inert or automatically harmless. Sun stressed that supplements enter the body’s metabolic pathways and can interact with existing medical conditions in complicated ways. Something that seems neutral or beneficial in one setting may behave differently in another, especially when the brain is already experiencing dementia-related changes.

For people with mild cognitive impairment or dementia who are currently taking glucosamine, the article suggests a practical next step: discuss it with a healthcare professional at the next visit. That conversation can help balance joint pain relief against possible, still uncertain cognitive risks and consider other options if needed. It can also be a good time to review all medications and supplements to be sure they still fit the person’s overall health needs.

What stands out in this research is how a simple joint supplement intersects with a complex brain process such as glycosylation. It shows how closely connected the body’s systems are and why careful study is needed before drawing conclusions about safety or benefit. The overall message is not to panic, but to stay informed and avoid making abrupt changes without professional advice. More research is needed before experts can recommend any specific changes for the general public or for people with cognitive conditions.

For now, the takeaway is measured. People without cognitive problems who take glucosamine for joint pain do not appear to be the focus of this concern. Those with mild cognitive impairment or dementia who use glucosamine may want to bring the study to their clinicians for individualized guidance. As always, dietary supplements are meant to support the diet, not to diagnose, treat, prevent, or cure disease. Anyone who is pregnant, nursing, or thinking about supplements for a child should consult a qualified healthcare provider before starting or stopping any product.